Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE.

J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.

2.

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.

Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR.

Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19.

3.

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C.

Gynecol Oncol. 2009 Oct;115(1):90-6. doi: 10.1016/j.ygyno.2009.05.042. Epub 2009 Jul 4.

PMID:
19577796
4.

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G.

Clin Cancer Res. 2009 Feb 15;15(4):1460-5. doi: 10.1158/1078-0432.CCR-08-1599.

5.

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.

Cancer. 2009 Jan 1;115(1):61-7. doi: 10.1002/cncr.24009.

6.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ.

J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.

7.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.

Eur Urol. 2008 Dec;54(6):1373-8. doi: 10.1016/j.eururo.2008.07.051. Epub 2008 Aug 8.

PMID:
18692304
8.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.

J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12.

PMID:
17997441
9.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

10.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

11.

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.

Cancer Biol Ther. 2006 Jan;5(1):22-7. Epub 2006 Jan 22.

PMID:
16357512
12.

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.

Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G.

Clin Cancer Res. 2005 Sep 15;11(18):6625-33.

13.

Mechanism of action of 2-methoxyestradiol: new developments.

Mooberry SL.

Drug Resist Updat. 2003 Dec;6(6):355-61. Review.

PMID:
14744499
14.

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P.

Cancer Cell. 2003 Apr;3(4):363-75.

15.

2-Methoxyestradiol, a promising anticancer agent.

Lakhani NJ, Sarkar MA, Venitz J, Figg WD.

Pharmacotherapy. 2003 Feb;23(2):165-72. Review.

PMID:
12587805
16.

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS.

Cancer Res. 2003 Jan 15;63(2):468-75.

17.

Mucoadhesive nanoparticulate systems for peptide drug delivery.

Takeuchi H, Yamamoto H, Kawashima Y.

Adv Drug Deliv Rev. 2001 Mar 23;47(1):39-54. Review.

PMID:
11251244
19.

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL.

J Clin Oncol. 1999 Sep;17(9):2859-67.

PMID:
10561363
Items per page

Supplemental Content

Write to the Help Desk